8120 Wisconsin Avenue
Bethesda, Maryland 20814

This exciting new event covers advanced technologies for physicochemical and biological characterization for a range of complex therapeutic proteins to provide a fuller understanding of the product, to ensure safety and efficacy, and to facilitate smooth and efficient interaction with the regulatory authorities. It focuses on advances in mass spectrometry, post-translational modifications, bioassays, characterization of impurities, and regulatory perspectives. The emphasis is on case studies, practical application, technology transfer and on fulfilling regulatory expectations.

Theresa LaVallee, Director of Research & Development will speak on the topics of "What and How to Establish Effective Science Driven Drug Development" and "Translational Sciences in Oncology: A Risk Mitigation Strategy"

Added by MedImmune on January 6, 2011

Interested 1